Active Projects on the 3T Siemens Scanner as of July 2021.
Click on a researcher’s name to learn more.
| Dr. Jiwon Oh | The Canadian Proactive Cohort Study for People Living with Multiple Sclerosis (CANPROCO) | Neurology |
| Dr. Tom Schweizer | Athlete traumatic brain injury, concussion and fMRI | Neurology |
| Dr. Jiwon Oh | Quantitative Spinal Cord MRI as a Biomarker of Treatment Response in MS: A Prospective Study | Neurology |
| Dr. Tom Schweizer | Investigating driving performance and underlying neural networks of aging cohorts and individuals with mild cognitive impairment and Alzheimer's disease | Neurology |
| Dr. Sakina Rizvi | A dimensional approach to evaluate reward processing in major depressive disorder before and after treatment with desveniafaxine | Neurology |
| Dr. Tom Schweizer | Understanding how disorders of the brain affect driving abilities: An fMRI driving-simulator study | Neurology |
| Dr. Sidney Kennedy | Identification of reward-based markers for risk of depression following mild traumatic brain injury | Neurology |
| Dr. Sakina Rizvi | Identifying the neural basis of capability for suicide | Neurology |
| Dr. Jiwon Oh | Quantitative Spinal Cord MRI in Radiologically Isolated Syndrome: A Prospective Study | Neurology |
| Dr. Sakina Rizvi | Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality | Neurology |
| Dr. Iqwal Mangat | OCEAN trial: Optimal anticoagulation for enhanced risk patient path-catheter ablation for atrial fibrillation | Neurology |
| Dr. Vinod Chandran (UHN) | Identifying Biomarkers for Joint Damage in Early Psoriatic Arthritis | Muskuloskeletal |
| Dr. Anish Kirpalani | A pilot study to access the role of magnetic resonance imaging in assessing kidney transplant injury following kidney transplantation | Nephrology |
| Dr. Corinne Fischer | A Phase III Multicenter randomized double-blind placebo-controlled parallel-group efficacy and safety study of Gantenerumab in patients with early (Prodromal to Mild) Alzheimer’s Disease | Neurology |
| Dr. Corinne Fischer | Validation of ocular measures as potential biomarkers for early detection of brain amyloid and neurodegeneration | Neurology |
| Dr. Anish Kirpalani | Functional Evaluation of Transplanted Kidneys in Outpatient Setting with Diffusion Weighted Magnetic Resonance Imaging and MR Elastography | Nephrology |
| Dr. Anish Kirpalani | OPTIMUM MRI PROTOCOL: Magnetic Resonance Imaging in Volunteers to Establish Optimum Protocols | Body |
| Dr. David Jenkins | MRI Enhanced dietary portfolio, exercise and heart risk | Body, Cardiology |
| Jefferson Wilson | Natural History of Mild Degenerative Cervical Myelopathy: an observational study | Neurology |
| Dr. Kim Connelly | Randomized double blind placebo controlled trial of Statins for the Primary Prevention of Heart Failure in patients wit cancer recieving anthracycline base chemotherapy - Pilot Study | Cardiology |
| Dr. Kim Connelly | The impact of diabetic microvascular dysfunction on late major adverse cardiac events post non-ST elevation acute coronary syndrome | Cardiology |
| Dr. Kim Connelly | Acute and chronic effects of Ivabradine upon cardiac structure and function and cerebral blood flow | Cardiology |
| Mohammed Al-omran | Study of Lipids Inside the Carotid with Evolocumab: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology prior to Carotid End Arterectomy | Neurology |
| John Graham | SPYRAL PIVOTAL | Body |
| Dr. Lisa Hicks | An Open-Label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), a Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis | Body |
| Jerry Teitel | Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (BeneGene-2) | Muskuloskeletal |
| Dr. Peter Vadas | A 3-Part randomized double-blind placebo-controlled Phase 2 study to evaluate safety and efficacy of Avapritinib (BLU-285) a Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately controlled with Standard Therapy | Neurology |
| Dr. Sunit Das | Advanced MRI to Detect Stem cell Niches in Glioblastoma | Neurology |
| Daniel Selchen | Multiple Sclerosis: Safety and Efficacy Study of Elezanumab (ABT-555) in Progressive Forms of Multiple Sclerosis | Neurology |
| Daniel Selchen | Multiple Sclerosis: Safety and Efficacy Study of Elezanumab (ABT-555) in Relapsing Forms of Multiple Sclerosis | Neurology |
| Daniel Selchen | A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects with Relapsing-Remitting Multiple Sclerosis Switching from Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment | Neurology |
| Dr. Magdy Elkhashab | A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis | Hepatology |
| Dr. Magdy Elkhashab | A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-316 (resmetirom) in Patients with Non-Alcoholic Streatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation | Hepatology |
| Dr. Magdy Elkhashab | A randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (TANDEM) | Hepatology |
| Dr. Magdy Elkhashab | A Phase 2, randomized, double-blind, double dummy, placebo-controlled, dose-ranging, dose-finding, parellel group study to assess efficacy and safety of PF-06865571 (OGAT21) alone and when coadministered with PF-05221304 (ACCI) in adult participants with biopsy-confirmed nonalcoholic steatohepatitis and fibrosis stage 2 or 3 | Hepatology |
| Reza Vosoughi | A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment - Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab Administration | Neurology |
| Reza Vosoughi | An Open-label, Single-arm 4-year study to evaluate effectiveness and safety of Ocrelizumab treatment in Patients with Progressive Multiple Sclerosis | Neurology |
| Reza Vosoughi | A Phase III multicentre randomized parallel-group double blinded placebo controlled study to evaluate the efficacy and safety of Ocrelizumab in adults with primary Progressive Multiple Sclerosis: ORATORIO Trial | Neurology |
| Dr. Iqwal Mangat | The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial: OCEAN | Cardiology |
| Michael Cuisimano | Validation of non-invasive rapid eye movements measurement as screening tool for mild traumatic brain injury | Neurosurgery |
| Dr. Sunit Das | Advanced MRI to Detect Stem Cell Niches in Glioblastoma | Neurosurgery |
| Ronald Goldberg (LMC) | A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Dose Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF 05221304 (ACCi) in Adult Participants with Biopsy Confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3 | Hepatology |
| Alex Abitol (LMC) | A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Dose Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF 05221304 (ACCi) in Adult Participants with Biopsy Confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3 | Hepatology |
| Harpreet Bajaj (LMC) | Novartis Pharmaceuticals - Canada - CLJN452D12201C, A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral therapy, compared to each monotherapy, for treatment of adult patients withtropifexor (LJN452) & licogliflozin (LIK066) combination nonalcoholic steatohepatitis (NASH) and liver fibrosis (ELIVATE) (Pro00040326) | Body |
